Foreign microorganisms are the normal targets of antibodies, but in approximately 5 % of us the capacity of the immune system to distinguish foreign from self breaks down, resulting in antibody production against our own tissues. The targets of autoimmune attack can be restricted to very specific elements of our bodies, such as the insulin-producing beta cells of the pancreas in Type I diabetes, or they can be fundamental building blocks of every tissue, such as DNA and chromatin which become targets of autoantibodies in systemic lupus erythematosus (SLE). What goes wrong in the subset of people that develop autoimmune disease? Cellular processes that normally prevent self-reactive lymphocytes from initiating antibody responses have at, last come into view ( Fig. 1 ), but until very recently nothing has been known of the molecular circuitry underpinning these important self-tolerance processes. Inherited faults in these molecular circuits nevertheless appear to be a key factor determining susceptibility or resistance to autoimmune disease, as diseases like Type I diabetes and SLE often run in families and have an elevated concordance in identical twins. The existence of mouse strains that inherit a high predisposition to autoimmune disease bears out the importance of genetic makeup in the development of autoimmunity. Pinpointing the molecules affected by these heritable differences has been difficult, however, because multiple genes appear to contribute to the cumulative risk of autoimmune disease in a complex manner.
Extraordinary progress in the last few years is now providing a striking view of an essential molecular circuit for maintaining self-tolerance, highlighted by two landmark papers published in recent issues of Science and Cell. Rieux-Laucat et al. [1] and Fisher et al. [2] independently describe' a total of eight children with an unusual and severe autoimmune disorder that is almost certainly due in part to their having inherited genes encoding defective versions of a lymphocyte cell-surface protein called Fas (also known as APO-1 or CD95). A picture of how Fas normally works to prevent autoimmunity is becoming clear, as described below, providing the first detailed view of the process dubbed by Ehrlich in 1900 as 'horror autotoxicus'.
A remarkable convergence between mouse genetics and human tumor immunology has led to the identification of Fas as a lynchpin in resistance to autoimmune disease [3] . In 1976, mouse geneticists at the Jackson Laboratories described a spontaneous recessive mutation, lymphoproliferation (pr), which resulted in the production of autoantibodies against DNA and chromatin, much as occurs in human SLE [4] . The lpr mutation also caused massive enlargement of lymph nodes by unusual CD4-CD8-T lymphocytes, a feature not usually seen in SLE. This characteristic of Ipr mice appears not to contribute to autoantibody production [5, 6] . Although the severity and penetrance of pr-associated autoantibodies and disease depends on genetic background [4] , the fact that Ipr was sufficient to cause autoimmunity essentially as a single-gene recessive trait facilitated both its chromosomal mapping and the construction of congenic mouse strains for powerful functional analyses (see below). An independent, complementing mutation with very similar characteristics and location, IprCg, was subsequently described in a subline of mice in Japan [7] .
In the late 1980s, tumor immunologists in Germany and Japan independently described monoclonal antibodies with the unusual property of triggering rapid lymphomacell death upon binding a molecule on the surface of human lymphoma cells [8, 9] . Molecular cloning revealed that the antigens, APO-1 and Fas, were identical and represented a membrane-spanning protein homologous to the receptors for tumor necrosis factor (TNF) and nerve growth factor (NGF), now known to be part of a large family of receptors [10, 11] . The human Fas gene mapped to a chromosomal region that was syntenic with the region in the mouse genome known to contain Ipr, and transcription of the mouse Fas gene was indeed found to be defective in Ipr mice [12] . Most tellingly, the Iprg mutation was found to be a single amino-acid substitution in the cytoplasmic tail of Fas [12] , in a site that has been defined as the 'death domain' based on functional studies of conserved regions in Fas and a related molecule, the TNF receptor, in cultured cells [3] .
The children described by Rieux-Laucat et al. [1] and Fisher et al. [2] carry analogous Fas mutations and have broadly similar symptoms to lpr mice, including both autoantibody production (although primarily to erythrocytes and platelets rather than chromatin) and lymphnode enlargement with unusual CD4-CD8-T lymphocytes [1, 2] . Several of the patients were unable to produce a stable cell-surface protein from their mutant Fas allele. Others produced truncated Fas molecules missing the death domain that, in one study, acted in a dominantnegative manner by interfering with cell-death induction by wild-type Fas upon expression in cultured cells. Lymphocytes from each of the children were inefficiently triggered into cell death by antibodies to Fas, compared with lymphocytes from disease-free siblings or parents.
Interestingly, two mothers of such children were found to express a dominant-negative mutant Fas [2] , while another mother expressed a similar potentially dominantnegative mutant Fas [1] , but in each case the mothers exhibited no disease [1, 2] . Conversely, a disease-free father displayed a defect in Fas-mediated apoptosis in vitro, despite his having no Fas defect, prompting speculation that he carried other genetic defects in the Fas pathway and transmitted these to his children to increase the penetrance of the heterozygous Fas mutation inherited from the mother [1] . These findings harken back to mouse studies showing that autoimmune disease in lpr animals is in fact a polygenic disorder, with other genes playing a major role in modifying the penetrance and severity of autoantibody production [4, 7] .
What does Fas do that is so crucial for maintaining selftolerance to fundamental building blocks like erythrocytes, platelets and DNA? Elegant studies of chimeric mice, constructed with mixtures of cells from congenic Ipr and wild-type donors whose lymphocytes and antibody products could be distinguished by allelic markers, have established that autoantibody production results only from B cells that are deficient in Fas, and only when Fas-deficient T cells are also present [13] [14] [15] . CD4 + T cells, which normally interact with B cells to promote antibody production against foreign microorganisms, were shown to be the necessary T-cell subset for autoantibody production in lpr animals [6] . These results, together with the need for a functional death domain in Fas, imply that Fas plays its essential role in self-tolerance by signaling the death of B and T lymphocytes.
When and where does Fas-mediated death of B and T cells occur to prevent autoimmune disease? An important fraction of B and T cells whose antigen receptors happen to bind to normal self-constituents are indeed eliminated by undergoing cell death soon after their formation in the bone marrow and thymus (Fig. 1) [16, 17] . Despite the fact that Fas is expressed by thymic T cells, elimination of self-reactive T and B cells in these primary lymphopoietic organs appears not to be perturbed when the cells carry defective Fas genes [18] [19] [20] .
Not all self-reactive lymphocytes are purged in the primary lymphopoietic organs, however, and the remainder are exported to the peripheral lymph nodes and. spleen, where immune responses against foreign microorganisms are normally initiated. It is in these sites that defects caused by Fas deficiency become apparent. CD4+ T cells that become activated upon binding an antigen in peripheral lymphoid tissues normally begin dividing to form an expanded clone, and at some point this expansion process is halted and corrected by death of the activated T cells (Fig. 1) [21-23] . Russell et al. [24] were the first of many to report a defect in this activation-induced cell death in Ipr T cells. It is now clear that this comes about by an autocrine or paracrine process involving the simultaneous expression of Fas and its ligand, FasL, on activated T cells [3, [25] [26] [27] .
The clonal expansion of CD4 + T cells that carry defective versions of Fas cannot be checked by this process, potentially allowing these cells to promote autoantibody production by self-reactive B cells. It is not yet known if Fas controls self-reactive CD4 + T cells in peripheral lymphoid tissues, or simply curtails T-cell responses to foreign antigens. The finding that Fas may preferentially induce death of those T cells that become activated by antigens in the absence of certain co-stimulatory signals, such as B7 or TNF [20, 28, 29] , nevertheless argues for a role in self-tolerance, as self antigens are normally encountered by T cells in the absence of these co-stimuli, whereas foreign microorganisms carry powerful triggers for co-stimulus production.
A direct role for Fas in eliminating self-reactive B cells in peripheral lymphoid tissues has recently been demonstrated. Rathmell et al. [30] found that self-reactive B cells that reach the spleen in a state of anergy -in which their antigen receptors can no longer transmit an activating signal -present self antigen to CD4 + T cells, but are killed instead of the usual outcome of clonal expansion and antibody secretion. Elimination of self-reactive B cells by this route depends on Fas expression by the B cells, and on normal FasL expression by the T cells; when either of these molecules are deficient, self-reactive B cells escape being killed by T cells and proceed to proliferate [30] .
An explanation for why anergic B cells might be killed by CD4+ T cells, whereas B cells that have been acutely activated by antigen proliferate, comes from in vitro studies by Rothstein et al. [31] . They demonstrated that naive B cells become highly susceptible to Fas-mediated killing when they are stimulated through CD40, a key receptor on the B cell for T-cell help, but that concurrent antigenreceptor engagement on the B cell in some way prevents transmission of the Fas death signal. Acute crosslinking of the B cell's antigen receptors, as would occur soon after an infection, may thus protect the B cell from Fastriggered death. By contrast, chronic receptor engagement by ubiquitous self antigens desensitizes the B cell's antigen receptors and renders the cell vulnerable to Fas-triggered death [30] .
Are these twin defects sufficient to explain autoimmunity and the production of autoantibodies in Fas-deficient mice and humans? The requirement for simultaneous defects in both B-and T-cell lineages [13] [14] [15] provides a strong foundation from which the results described above can be assembled into a model of autoimmunity caused by defects in Fas-dependent tolerance checkpoints (Fig.  2) . Autoreactive CD4+ T cells that escape thymic censoring, for example because of insufficient exposure to autoantigen, can potentially be stimulated by autoantigens in the periphery. Normally these cells may pose little risk because autoantigen stimulation is not accompanied by co-stimuli, such as the B7 ligands for CD28, that are needed to produce enough interleukin 2 (IL-2) for clonal expansion. If sufficient IL-2 is received from neighboring T cells [22] , however, Fas may then play a key role in aborting the autoreactive T cell because of the missing CD28 or TNF co-stimuli [28, 29] .
The activation of Fas-deficient autoreactive T cells cannot be aborted by this route, and instead they continue to be stimulated by self-antigen and proliferate. When autoreactive B cells present self antigens to these rogue T cells, the T cells display on their surface both the CD40 ligand (CD40L) and FasL. Normally, the Fas signal would trigger the death of the self-reactive B cell because of the lack of antigen-receptor signalling from their desensitized receptors. If the B cells are Fas deficient, however, they too escape death and instead are stimulated by CD40 to proliferate. As the surviving B and T cells continue to interact and form expanded forbidden clones, some of the B cells differentiate into plasma cells that produce autoantibodies.
A key question that remains unanswered concerns the genes that modify the severity and penetrance of Fas-associated disease. For example, why do only some carriers of DISPATCH 1221 the Fas defects described by Rieux-Laucat et al. [1] and Fisher et al. [2] develop autoimmune disease, and why do lpr mice only develop certain autoantibodies and disease after a long latent period that is strongly influenced by other genes [4] ? By analogy with inherited susceptibility to cancer, other defects in the Fas circuit or in other checkpoints for censoring self-reactive cells, such as germinal-center elimination of B cells or negative selection of thymocytes (Fig. 1) , may need to be present either as inherited alleles or as somatically acquired mutations [7] . Finally, while most individuals with SLE probably do not carry defective copies of Fas, it remains to be explored whether other genes in the circuit are faulty. The example of Fas defects thus provides an entry point into the molecular anatomy of autoimmunity and a paradigm for how mouse genetics and human clinical research can be brought to bear on this fundamental problem.
